The FDA receives raw and cleaned datasets from sponsors, not just summary reports. Their internal teams conduct independent analyses, which can lead to findings or data presentations in the official drug label that differ from or expand upon what's in the published paper.

The success of the U.S. clinical trial infrastructure is not abstract. According to the American Cancer Society, this system is directly responsible for saving over 4 million lives between 1995 and 2025. This quantifies the immense public health impact of systematic research, demonstrating that without trials, progress in reducing cancer mortality would stagnate.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

AI is poised to revolutionize evidence synthesis by automating the grueling, multi-year process of systematic reviews. The ultimate goal is to enable anyone to get an accurate, near-instantaneous summary of the entire body of research on a specific question, effectively creating meta-analysis on demand.

Unlike controlled clinical trial data, real-world evidence is derived from vast, messy, and incomplete data from daily healthcare. This variability is its strength, offering deeper insights into long-term outcomes, drug interactions, and diverse patient populations that clean trial data misses.

Medicine excels at following standardized algorithms for acute issues like heart attacks but struggles with complex, multifactorial illnesses that lack a clear diagnostic path. This systemic design, not just individual doctors, is why complex patients often feel lost.

Evidence-based medicine became standard because doctors are taught it in medical school and face legal/professional consequences for ignoring guidelines. Fields like education and conservation struggle with adoption because they lack this powerful combination of mandatory training and strong accountability mechanisms for practitioners.

Frontier AI models excel in medicine less because of their encyclopedic knowledge and more because of their ability to integrate huge amounts of context. They can synthesize a patient's entire medical history with the latest research—a task difficult for any single human. This highlights that the key to unlocking AI's value is feeding it comprehensive data, as context is the primary driver of superhuman performance.